Method for treating chronic wounds with an extracellular polymeric substance solvating system
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61B-017/3203
A61K-031/19
A61K-031/192
A61K-031/194
A61K-033/22
A61B-017/3205
A61K-031/198
A61K-045/06
A61K-031/09
A61K-031/7036
A61K-047/12
A61K-047/20
A61B-017/32
출원번호
US-0314974
(2014-06-25)
등록번호
US-9700344
(2017-07-11)
발명자
/ 주소
Myntti, Matthew F.
Oliver, Dana A.
Hissong, James B.
Medina, Jennifer G.
출원인 / 주소
MEDTRONIC XOMED, INC.
대리인 / 주소
Patterson Thuente Pedersen, PA
인용정보
피인용 횟수 :
0인용 특허 :
101
초록▼
Chronic wounds may be treated by debriding necrotic and other devitalized tissue from the wound, and applying to the wound an extracellular polymeric substance solvating system comprising a metal ion sequestering agent, surfactant and buffering agent. The solvating system disrupts biofilms which may
Chronic wounds may be treated by debriding necrotic and other devitalized tissue from the wound, and applying to the wound an extracellular polymeric substance solvating system comprising a metal ion sequestering agent, surfactant and buffering agent. The solvating system disrupts biofilms which may be present in the wound and aids or enables the resumption of normal healing.
대표청구항▼
1. An apparatus for treating a chronic wound, comprising: a) a debriding device comprising a reservoir containing an extracellular polymeric substance solvating system comprising an aqueous solution of a metal ion sequestering agent, surfactant and buffering agent wherein the solvating system has an
1. An apparatus for treating a chronic wound, comprising: a) a debriding device comprising a reservoir containing an extracellular polymeric substance solvating system comprising an aqueous solution of a metal ion sequestering agent, surfactant and buffering agent wherein the solvating system has an osmolarity of about 1,000-4,000 milliosmoles of solute per liter, and wherein the reservoir is in fluid communication with an applicator for applying the solvating system to a wound at a sufficient flow rate or under sufficient pressure to debride at least some devitalized tissue from the wound; andb) an aspirating device which removes at least some debrided necrotic or other devitalized tissue and excess solvating system from the wound. 2. An apparatus according to claim 1 wherein the applicator applies the solvating system at a flow rate more than 7 and less than 20 cm3/sec. 3. An apparatus according to claim 1 wherein the applicator applies the solvating system at a delivery pressure of about 30 to about 500 KPa. 4. An apparatus according to claim 1 wherein the applicator applies the solvating system at a delivery pressure of about 60 to about 350 KPa. 5. An apparatus according to claim 1 wherein the metal ion sequestering agent comprises a mild acid whose acidity is sufficient to sequester one or more metal ions in a bacterial biofilm but which is not so acidic so as to harm healthy or healable tissue in the wound. 6. An apparatus according to claim 1 wherein the metal ion sequestering agent comprises a sequestering agent for sodium, calcium or iron. 7. An apparatus according to claim 1 wherein the metal ion sequestering agent comprises a carboxylic acid, diacid, triacid or mixture thereof. 8. An apparatus according to claim 1 wherein the metal ion sequestering agent comprises formic acid, acetic acid, chloroacetic acid, dichloroacetic acid, oxalic acid, oxamic acid, glycolic acid, lactic acid, pyruvic acid, aspartic acid, fumaric acid, maleic acid, succinic acid, iminodiacetic acid, glutaric acid, 2-ketoglutaric acid, glutamic acid, adipic acid, glucuronic acid, mucic acid, nitrilotriacetic acid, salicylic acid, ketopimelic acid, benzoic acid, mandelic acid, chloromandelic acid, phenylacetic acid, phthalic acid, boric acid or mixture thereof. 9. An apparatus according to claim 1 wherein the metal ion sequestering agent comprises citric acid. 10. An apparatus according to claim 1 wherein the surfactant comprises an alkyl sulfate, alkyl sulfonate or aryl sulfonate or mixture thereof. 11. An apparatus according to claim 1 wherein the solvating system comprises at least about 0.01 M of metal ion sequestering agent and at least about 0.002 M of surfactant. 12. An apparatus according to claim 1 wherein the buffering agent maintains the solvating system at an appropriate pH for contacting chronic skin wounds. 13. An apparatus according to claim 1 wherein the solvating system has an osmolarity of about 1,500 to about 2,600 milliosmoles of solute per liter. 14. An apparatus according to claim 1 wherein the solvating system breaks down bacterial biofilms in chronic wounds. 15. An apparatus according to claim 1 wherein the solvating system aids in chronic wound biofilm detachment, removal or disruption. 16. An apparatus according to claim 1 wherein the solvating system further comprises an antimicrobial agent. 17. An apparatus according to claim 16 wherein the antimicrobial agent comprises a topical antibiotic. 18. An apparatus according to claim 16 wherein the antimicrobial agent comprises a peptide. 19. An apparatus according to claim 16 wherein the antimicrobial agent comprises a bacterially selective peptide. 20. An apparatus according to claim 16 wherein the antimicrobial agent comprises gallium acetoacetonate, gallium bromide, gallium chloride, gallium fluoride, gallium iodide, gallium maltolate, gallium nitrate, gallium nitride, gallium percolate, gallium phosphite, gallium sulfate or mixture thereof. 21. A patient care kit for treating a chronic wound, the kit comprising a tray; syringe; vessel containing an extracellular polymeric substance solvating system comprising an aqueous solution of a metal ion sequestering agent, surfactant and buffering agent wherein the solvating system has an osmolarity of about 1,000-4,000 milliosmoles of solute per liter; and printed instructions describing the proper use of the kit for treating chronic wounds. 22. A product comprising an extracellular polymeric substance solvating system for use in treatment of chronic skin wounds, the solvating system comprising an aqueous solution of at least about 0.01 M of metal ion sequestering agent, at least about 0.002 M of surfactant, and buffering agent that maintains the solvating system at an appropriate pH for contacting chronic skin wounds, wherein the solvating system has an osmolarity of about 1,000-4,000 milliosmoles of solute per liter, a sufficiently low viscosity to enable delivery to the wound using spray application, and aids in chronic wound biofilm detachment, removal or disruption.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (101)
Roselle, Brian Joseph; Tollens, Fernando Ray; Rollins, David Kent; Jervier, Gregory Leo; Delgado, Rodolfo, Acidic antimicrobial compositions for treating food and food contact surfaces and methods of use thereof.
Osbakken,Robert S.; Hale,Mary Anne; Leivo,Frederick T.; Munk,James D., Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis.
Michael A. Repka ; Staci L. Repka ; James W. McGinity, Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof.
Rees, Wayne M.; Hilgers, Debra S., Biocidal cleaner composition containing acid-anionic surfactant-alcohol combinations and method of using the composition.
Hatton Anthony Guy,GBX ; Scott Hugh,GBX ; Hilton Jane Elizabeth,GBX, Calcium mupirocin non-aqueous nasal spray for otitis media or for recurrent acute bacterial sinusitis.
Schwartz, Herbert E.; Blackmore, John M.; Cortese, Stephanie M.; Oppelt, William G., Compositions of polyacids and polyethers and methods for their use in reducing adhesions.
Arenberg, Irving K.; Arenberg, Michael H.; Lemke, Christine; Berglund, John A., Controlled release system for delivering therapeutic agents into the inner ear.
Muni,Ketan P.; Ha,Hung V.; Makower,Joshua; Morriss,John H.; Chang,John Y.; Facteau,William M.; Walke,Amrish Jayprakash, Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders.
Schlesinger Larry S. ; Britigan Bradley E., Gallium-containing compounds for the treatment of infections caused by intracellular pathogens and pathogens causing chronic pulmonary infection.
della Valle Francesco (Padova ITX) Romeo Aurelio (Rome ITX) Lorenzi Silvana (Padova ITX), Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same.
Edwardson Peter A. D.,GBX ; Fairbrother John E.,GBX ; Gardner Ronald S.,GBX ; Hollingsbee Derek A.,GBX ; Cederholm-Williams Stewart A.,GBX, Kit for preparing a fibrin sealant.
Gerald Cagle ; Robert L. Abshire ; David W. Stroman ; John M. Yanni, Methods of treating ophthalmic, otic and nasal infections and attendant inflammation.
Romeo Aurelio,ITX ; Silvestrini Bruno,ITX ; Kirschner Gunter,ITX, Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics.
Wallace Donald G. ; Cruise Gregory M. ; Rhee Woonza M. ; Schroeder Jacqueline Anne ; Coker ; III George T. ; Maroney Marcee M., Rapid gelling biocompatible polymer composition.
della Valle Francesco (Padova ITX) Romeo Aurelio (Rome ITX) Lorenzi Silvana (Padova ITX), Salts and mixtures of hyaluronic acid with pharmaceutically active substances, pharmaceutical compositions containing th.
Michal, Eugene T.; Buchko, Christopher J.; Kilpatrick, Deborah L.; Bigus, Stephen J., Superoxide dismutase or superoxide dismutase mimic coating for an intracorporeal medical device.
Brian Andrew Hills AU; Derek Alan Woodcock GB, Use of surface active agent for the manufacture of a medicament for treatment of disorders of the middle ear.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.